RxDoctor Payments Data

Maninder Kahlon, MD

Neurology · Sun City, AZNPI 1184695165

Payments from drug & device makers

$23,075in general payments, 2019–2025

Across 1,237 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • UCB, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$1K
  • Genentech USA, Inc.$1K
  • Amneal Pharmaceuticals LLC$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1901%
  • Food & beverage$20,08398%
  • Education$2371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.83$3,614
UCB, Inc.143$2,045
AbbVie(2 entities)120$1,724
SK Life Science, Inc.71$1,317
Genentech USA, Inc.54$1,270
Amneal Pharmaceuticals LLC84$1,160
Novartis68$1,077
Acadia Pharmaceuticals Inc71$969
Argenx US, Inc.58$944
AstraZeneca35$843
Pfizer33$679
Biogen43$580
Amgen(2 entities)22$539
Eisai Inc.24$498
Abbott27$483
Medtronic(2 entities)15$435
Kyowa Kirin, Inc.22$370
Bristol Myers Squibb21$367
Lilly USA, LLC21$355
Harmony Biosciences LLC15$325
Upsher-smith Laboratories LLC24$308
Lundbeck LLC20$286
Neurelis, Inc.13$205
MDD US Operations, LLC7$185
TG Therapeutics, Inc.9$154
Jazz Pharmaceuticals Inc.2$140
Grifols USA, LLC8$139
Acorda Therapeutics, Inc9$133
Supernus Pharmaceuticals, Inc.7$131
Merz North America, Inc.5$122
Octapharma USA, Inc.3$119
Neurocrine Biosciences, Inc.6$116
Biohaven Pharmaceuticals, Inc.10$111
Corium, LLC11$99
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$97
Sanofi6$86
Sumitomo Pharma America, Inc.5$82
Takeda Pharmaceuticals U.S.A., Inc.4$70
EMD Serono, Inc.5$63
Mallinckrodt Hospital Products Inc.4$63
CSL Behring3$51
Avion Pharmaceuticals3$50
Biohaven Pharmaceutical Holding Company Ltd.3$47
Shire North American Group Inc3$46
Ipsen Biopharmaceuticals, Inc2$41
Otsuka America Pharmaceutical, Inc.2$40
Scilex Pharmaceuticals Inc.2$32
Alnylam Pharmaceuticals Inc.2$32
Nevro Corp.1$29
Mallinckrodt Enterprises LLC2$29
E.r. Squibb & Sons, L.L.C.2$28
Tanabe Pharma America, Inc.2$28
Banner Life Sciences, LLC2$26
Catalyst Pharmaceuticals, Inc.1$25
Merz Pharmaceuticals, LLC1$25
Livanova USA, Inc.2$25
Boston Scientific2$24
Vertiflex, Inc.1$24
Insightec,inc1$23
Impel Pharmaceuticals Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,075 in reported general payments places this provider in the 70th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$2,218,515
Medicare patients
1,577
Services billed
53,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4615$184,689
NeuproRotigotine25$43,828
Memantine Hcl1,596$29,195
Duloxetine Hcl1,292$26,257
Emgality PenGalcanezumab-Gnlm24$21,279
RexultiBrexpiprazole15$21,086
RytaryCarbidopa/Levodopa17$14,584
Gabapentin599$12,701
Topiramate733$10,856
Scopolamine49$5,633
Levetiracetam128$4,834
Memantine Hcl ErMemantine Hcl31$4,710
Divalproex Sodium176$4,263
Lacosamide27$4,194
Donepezil Hcl187$3,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro$2,045$43,82825 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$21,08615 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,160$16,65439 claims
Upsher-smith Laboratories LLCTopiramate$308$10,856733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 neurology providers in Arizona.

Other neurology in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →